We have previously described the rates of oxidation for long-chain fatty acids and glucose in stunned myocardium during early reflow after moderately severe regional ischemia. The purpose of these studies was to characterize the rates of pyruvate and lactate oxidation during comparable periods of reflow. In the main protocol, pyruvate oxidation was defined at two conditions of coronary flow and at two levels of fatty acids in the coronary perfusate. Twenty animals were prepared using the extracorporeally perfused, working swine heart model. In five control (group 1) hearts, flow in the left anterior descending coronary artery was maintained at aerobic levels during a 115-minute perfusion trial. In 15 hearts (groups 2 and 3), flow was held at aerobic levels for 30 minutes, reduced acutely by 60% for 45 minutes, and restored again to aerobic levels for the final 40-minute reflow. In the five control hearts and in 10 of the reperfused hearts (group 2), 20% Intralipid (KabiVitrum, Alameda, California) with heparin was infused to raise serum fatty acids to an average of 0.95+±0.08 ,umol/ml, whereas in the five remaining nonsupplemented group 3 hearts, serum levels of fatty acids were 0.49±+0.10 ,umol/ml. Ischemia in supplemented and nonsupplemented hearts caused a decline in regional mechanical performance (-40A% and -39A% below aerobic values in active shortening) that failed to recover completely (-16A% and -25A% below aerobic values in active shortening) during reflow. Myocardial oxygen consumption in regionally hypoperfused hearts followed trends similar to those of mechanical function, with declines of -43A% and -461% during ischemia and -14A% and -23A% during reflow. Pyruvate oxidation in hearts receiving excess fatty acids decreased by 50% during ischemia (p<0.001 compared with aerobic values) and failed to recover during reflow (-119% below ischemic values, p <0.002 compared with aerobic values). Pyruvate oxidation in hearts perfused at physiological levels of fatty acids similarly decreased by 55% during ischemia (p<0.05 compared with aerobic values) and failed to recover during reflow (levels comparable to ischemic values, p<0.05 compared with aerobic values). There were no statistical differences in rates of pyruvate oxidation between group 2 and group 3 hearts in any of the three perfusion (aerobic, ischemic, reflow) intervals. Lactate oxidation in four additional animals that were prepared and perfused comparably declined 39A% below aerobic values during ischemia and decreased 47A% during reflow. These data indicate that pyruvate and lactate oxidations are depressed in the early reperfusion period, probably as a consequence of the inhibition affected by the preferred oxidation of long-chain fatty acids. (Circulation Research 1990;66:282-288) G lycolysis in cardiac muscle perfused with mixed substrates is approximately related inversely to coronary flow such that during myocardial ischemia, except in the most profound instances of coronary flow restriction, glucose metabolism is accelerated.12 Levels of continued metabolic performance during hypoperfusion are predicated on From the Section
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We have previously described the rates of oxidation for long-chain fatty acids and glucose in stunned myocardium during early reflow after moderately severe regional ischemia. The purpose of these studies was to characterize the rates of pyruvate and lactate oxidation during comparable periods of reflow. In the main protocol, pyruvate oxidation was defined at two conditions of coronary flow and at two levels of fatty acids in the coronary perfusate. Twenty animals were prepared using the extracorporeally perfused, working swine heart model. In five control (group 1) hearts, flow in the left anterior descending coronary artery was maintained at aerobic levels during a 115-minute perfusion trial. In 15 hearts (groups 2 and 3), flow was held at aerobic levels for 30 minutes, reduced acutely by 60% for 45 minutes, and restored again to aerobic levels for the final 40-minute reflow. In the five control hearts and in 10 of the reperfused hearts (group 2), 20% Intralipid (KabiVitrum, Alameda, California) with heparin was infused to raise serum fatty acids to an average of 0.95+±0.08 ,umol/ml, whereas in the five remaining nonsupplemented group 3 hearts, serum levels of fatty acids were 0.49±+0. 10 ,umol/ml. Ischemia in supplemented and nonsupplemented hearts caused a decline in regional mechanical performance (-40A% and -39A% below aerobic values in active shortening) that failed to recover completely (-16A% and -25A% below aerobic values in active shortening) during reflow. Myocardial oxygen consumption in regionally hypoperfused hearts followed trends similar to those of mechanical function, with declines of -43A% and -461% during ischemia and -14A% and -23A% during reflow. Pyruvate oxidation in hearts receiving excess fatty acids decreased by 50% during ischemia (p<0.001 compared with aerobic values) and failed to recover during reflow (-119% below ischemic values, p <0.002 compared with aerobic values). Pyruvate oxidation in hearts perfused at physiological levels of fatty acids similarly decreased by 55% during ischemia (p<0.05 compared with aerobic values) and failed to recover during reflow (levels comparable to ischemic values, p<0.05 compared with aerobic values). There were no statistical differences in rates of pyruvate oxidation between group 2 and group 3 hearts in any of the three perfusion (aerobic, ischemic, reflow) intervals. Lactate oxidation in four additional animals that were prepared and perfused comparably declined 39A% below aerobic values during ischemia and decreased 47A% during reflow. These data indicate that pyruvate and lactate oxidations are depressed in the early reperfusion period, probably as a consequence of the inhibition affected by the preferred oxidation of long-chain fatty acids. `4C]glucose showed that glucose uptake was indeed increased during reperfusion but that the majority of the substrate was used only in nonoxidative glycolysis. This is in agreement with data from our laboratory using the intact, working swine heart preparation and`4C-labeled palmitate and glucose, which showed high rates of oxidation of fatty acids during reperfusion and much lower rates of glucose oxidation.10," We demonstrated during 1 hour of reperfusion following 45 minutes of ischemia in perfused pig hearts an 89-111A% rebound of 14C02 production above aerobic values for fatty acids, which remained the substrate of choice. The purpose of the present study is to further characterize rates of oxidation of other carbohydrate analogues, chiefly pyruvate, which is reportedly used in preference to glucose in the reflow setting.12 Measurements were obtained at two conditions of coronary perfusion and at two levels of fatty acids in the perfusate. Rates of pyruvate oxidation and their directional shifts with ischemia and reperfusion were contrasted with those for lactate. Our hypothesis remains that because of the preference for and high utilization of fatty acids by heart muscle during reflow, oxidation of pyruvate and lactate will be low.
Materials and Methods
Twenty-four adolescent swine weighing 50.3+±1.3 kg were studied after anesthesia with pentobarbital (35 mg/kg i.v.) and the establishment of controlled positive-pressure ventilation using oxygen-supplemented room air. The preparation used in this study has been extensively reported elsewhere.13-'6 Briefly, the coronary arteries were perfused separately through an anterioarterial shunt connected extracorporeally. Blood was withdrawn from a femoral artery and returned by three low-flow perfusion pumps to proximally cannulated right, main left, and left anterior descending (LAD) coronary arteries. Included in the LAD circuit was a 100-ml mixing chamber used to receive a constant infusion of labeled substrate (about 49 ,Ci of either pyruvate or lactate/animal) for mixing with the coronary perfusate before its infusion into the myocardium. Aerobic flows were adjusted so that coronary perfusion pressures approximated arterial pressures and the venous oxygen saturation was maintained at or about 39%. Venous cannulas were inserted into the great cardiac vein anteriorly and used with ports in the arterial lines to sample for gases and metabolites. Left ventricular pressure and its maximal first derivative were measured by a high-fidelity manometer-tipped pressure device (Millar Instruments, Houston, Texas) placed in the left ventricular chamber. Regional function was estimated from myocardial shortening as measured by ultrasonic crystals placed at midmyocardial depth in the LAD perfusion system. Segment shortening was used to characterize regional contractility. Right coronary and left circumflex flows were held at aerobic flows throughout the experiments. In 19 hearts receiving either labeled pyruvate or lactate, LAD flow was maintained at aerobic levels for the first 30 minutes of perfusion, reduced by 60% for the next 45 minutes, and then returned to aerobic levels for the final 40 minutes. In five additional hearts receiving labeled pyruvate, LAD flow was kept at nonischemic levels throughout the studies. To set a condition of near-constant myocardial oxygen demand in all hearts, blood volumes were replenished with 6% dextran in saline to maintain systemic pressures at approximately 100 mm Hg. Serum glucose was continuously monitored and maintained at 6.7+0.4 gmol/ml with intravenous injections of dextrose. [2-14C]Pyruvate (3.0-4.1x 106 dpm/ml) was infused into the LAD coronary circulation at 0.5 ml/min (0.05-0.07 ,umol pyruvate/min) during aerobic perfusion in 20 hearts and at 0.5 ml/min and 0.2 ml/min (0.02-0.03 ,mol/min) in the 15 hearts undergoing ischemia/reflow. ['4C]Lactate (ul) (2.8x 106 dpm/ml) was similarly infused into the LAD circulation in four additional hearts at 0.004 ,umol/min during aerobic and reperfusion conditions and at 0.001 ,umol/min during ischemia. To maintain serum fatty acid levels sufficient to compare with previous data,10 19 animals receiving either labeled pyruvate or lactate also received excess free fatty acids administered as a constant infusion of 20% Intralipid (0.8 mg/min/kg; KabiVitrum, Alameda, California) with heparin throughout the studies, beginning at 0 minutes of perfusion. Indocyanine green indicator (0.33 mg/ml) was infused into the mixing chamber of the LAD perfusate for 5 minutes at a flow rate of 1.0 ml/min during aerobic perfusion and reperfusion and at 0.4 ml/min during ischemia. Samples of arterial and venous blood from the LAD circuit were collected at 30, 70, and 105 minutes of perfusion to measure for any unlabeled coronary blood entering the venous system of the LAD circuit. A similar method used to estimate this dilution was described previously. 15 In the 19 ischemia/reflow hearts, the dilution factor (K) obtained in the present studies was 0.91+0.01, 0.78±0.02, and 0.90+0.01 for the aerobic, ischemic, and reperfusion periods, respectively. For the five animals held at aerobic flows throughout, the values were 0.85+±0.10, 0.90±0.04, and 0.91±0.02 at the same time periods, respectively.
Metabolic and mechanical data were obtained at 5or 10-minute intervals throughout the studies. Regional myocardial oxygen consumption (MVO2 in mmol/hr/g dry wt) and 14C02 production from labeled pyruvate and lactate oxidation (gmol/hr/g dry wt) were obtained together with serum fatty acids (gmol/ml) as described previously.'3"15"17
We determined (see below) that the amount of pyruvate distributed into the red cells of the perfusate was relatively small (about 12% of whole blood) where zA14CO2 is the difference between venous and arterial 14C02 in coronary perfusate, dpm/ml; Q ADis flow in the LAD bed, ml/min; K is indocyanine green dilution factor; and ASA (arterial specific activity of pyruvate in dpm/,mol) is the ratio of (Ax B)/ QLADX C), where A is the radioactivity concentration of 14C-pyruvate infused, dpm/ml; B is the infusion rate of labeled pyruvate, ml/min; and C is the arterial pyruvate concentration, ,umol/ml. The formula for estimating lactate oxidation was identical to that of pyruvate oxidation with the obvious substitutions: 14C02 is that derived from labeled lactate, ASA is the arterial specific activity of lactate, A is the radioactivity concentration of [14C]lactate, B is the infusion rate of labeled lactate, and C is the arterial lactate concentration. All units are identical to those in the pyruvate formula. The amount of lactate distributed into the red cells of the perfusate was 12% and thus was not included in the calculation of plasma specific activity for lactate.
The tissue perfused by the LAD artery was determined at the conclusion of each study by injecting India ink down the LAD cannula. LAD myocardium was dissected free from that perfused by the combined right and left circumflex arteries, and both perfusion systems were weighed.
Analysis of Samples
Ten-milliliter aliquots of blood were taken from the LAD artery and vein at 10-minute intervals throughout the studies. One milliliter of this blood in triplicate was used for '4CO2 determinations from labeled pyruvate and lactate, while the remainder was centrifuged at 1,500g at 4°C for 10 minutes to yield about 3.0 ml plasma. A 3-ml aliquot of blood from the femoral artery was also centrifuged to obtain a similar plasma fraction. These plasma samples from the LAD artery, vein, and femoral artery were counted to measure total radiocarbon in the blood. The contamination of labeled pyruvate or lactate spilling from the coronary perfusate into the systemic circulation as monitored in the femoral artery was approximately 6% at 10 minutes, and it increased steadily during the studies to about 16-18% at 105 minutes. At 105 minutes, about 25% of the radioactivity of this contaminant consisted of pyruvate, with the remainder lactate.
The distribution of pyruvate between plasma and red blood cells was analyzed by us to determine if the majority of substrate remained in the plasma. About 25 ml of whole blood was collected, and an aliquot was centrifuged at 1,500g at 4°C for 10 minutes to obtain plasma and red blood cells. One milliliter of 0.6 M perchloric acid was then added to 1 ml of either whole blood, plasma, or red blood cells and centrifuged again at 1,500g at 40 C for 10 minutes to remove precipitated protein. The supernatants obtained were analyzed with high-performance liquid chromatography for pyruvate and lactate distributions. Pyruvate and lactate were analyzed on a Bio-Rad (Cambridge, Massachusetts) Aminex HPX-87H column (300 x 7.8 mm) using 0.01N sulfuric acid with a flow rate of 0.6 ml/min and absorbance detected at 193 nm. Pyruvate and lactate concentrations in red blood cells (normalized to whole blood) were only 12% of that in whole blood. This agrees with previously published human data.1819 Calculations of specific activity of pyruvate and lactate in blood were therefore based on the assumption that the vast majority of measured substrate was contained in plasma and not importantly distributed into erythrocytes.
Statistical comparisons of data were made in all groups using paired Student's t tests and, among the three groups receiving labeled pyruvate, by a twocomponent a posteriori analysis of variance followed by a studentized Newman-Keul's t test.20 Statistical significance was defined by two-tailed values of p<0.05. Data are reported as mean±SEM and, where indicated, include all the data per group within a given perfusion interval; that is, the aerobic perfusion interval encompassed perfusion times 0, 10, 20, and 30 minutes; the ischemic interval, 40, 50, 60, 70, and 75 minutes; and the reperfusion interval, 85, 95, 105, and 115 minutes.
Results
Controlled variables for coronary flow, serum fatty acids, blood sugar, and left ventricular pressure for Group 2 hearts in the presence of excess fatty acids showed a decline in pyruvate oxidation during ischemia that failed to recover at all during reperfusion. Group 3 hearts in the presence ofphysiological levels offatty acids showed similar decreases in oxidation duning ischemia and reperfusion. 0 25 50 75 100 125 PERFUSION TIME (min) 150 FIGURE 1. Regional motion (panel A) as measured by ultrasonic crystals in left anterior descending (LAD) coronary artery myocardium for the three groups of pyruvate hearts. Group 1 hearts maintained regional performance throughout the perfusion trial, whereas group 2 and group 3 hearts evinced mechanical stunning during reflow. Regional oxygen consumption (panel B) in LAD myocardium showed similar trends among the three groups. the three pyruvate heart groups are listed in Table 1 . By Newman-Keul's t test, there were no statistical differences among groups for any of the variables as compared by either groups or by perfusion interval except for 1) the expected differences in LAD flow between groups 1 and 2 (p<0.001) and between groups 1 and 3 (p<0.001) during the 40-75-minute interval and 2) the expected differences in perfusate fatty acids between groups 2 and 3 (p<0.001). Unexpectedly, despite augmentation, serum fatty acids in group 1 hearts did not achieve levels accomplished in group 2 hearts, and the difference was significant (p<0.01).
Regional mechanical performance as estimated by percent active shortening for the three pyruvate heart groups is shown in Figure 1A . Group 1 aerobic hearts maintained normal performance throughout the perfusion trial, whereas group 2 and group 3 hearts responded to the hypoperfusion interval with an anticipated decline in shortening from their respective preischemic values of 40% and 39% (p<0.001 and p<0.001, respectively). Motion failed to recover completely in group 2 hearts during reperfusion and remained at 16% (p<O0.05) below aerobic values. Group 3 shortening was 25% below preischemic values and was not statistically different from either preischemic or ischemic values.
Regional oxygen consumption ( Figure 1B) showed shifts similar to those of regional shortening in the three pyruvate heart groups. Group 1 aerobic hearts showed no significant changes in oxygen consumption throughout the perfusion trials (1.4+0.1, 1.4+0.1, and 1.5+0.1 mmol/hr/g dry wt for the 0-30-minute, 30-75-minute, and 75-115-minute perfusion intervals, respectively). In group 2 and group 3 hearts, oxygen consumption was reduced significantly during ischemia (-43A% and -46A%, p<0.001 and p<0.001, respectively) and recovered incompletely during reflow (-14/A% and -23A% below preischemic values, NS different and p<O0.001, respectively).
Rates of pyruvate oxidation in the three heart groups (Figure 2 ) differed, in part, in pattern from those noted for regional oxygen consumption. In group 1 aerobic hearts, pyruvate oxidation was relatively fixed throughout the perfusion trial (4.2±0.6, 3.9±0.7, and 4.4+0.9 gmol/hr/g dry wt for the 0- Intergroup comparisons by perfusion interval using Newman-Keul's statistical analysis showed the expected differences between group 1 hearts and either group 2 or group 3 hearts during ischemia (p<0.025 at least) and reflow (p<0.005 at least) but no difference between group 2 and group 3 hearts among any of the perfusion intervals.
As a final study, myocardial lactate oxidation was measured in four additionally perfused swine hearts. Controlled variables were comparable with those of the main study: right and left circumflex coronary flows, 12.3 + 1.9 ml/min/g dry wt; LAD coronary flow, 8.6+ 1.2, 3.4+0.5, and 8.6± 1.2 ml/min/g dry wt for the preischemic, ischemic, and reperfusion intervals, respectively; left ventricular pressure, 100.6±0.9 mm Hg; serum fatty acids, 0.69±0.10 gmol/ml; and blood glucose, 6.8+0.4 ,umol/ml. During ischemia, lactate oxidation decreased 39% (from 178.1±50.3 to 109.3±31.9 ,umol/hr/g dry wt) and during reflow decreased 47% below preischemic values (94.9±32.0 ,umol/hr/g dry wt).
Discussion
The purpose of this report was to detail the rates of oxidation of pyruvate and lactate during early myocardial reperfusion after ischemia in heart muscle with incomplete mechanical recovery. The intact working swine heart preparation has proved useful as a model for evaluating myocardial reperfusion in that it develops demonstrable mild-to-moderate mechanical stunning during reflow and has shown rapid return of fatty acid oxidation and preferred use of this substrate for repletion of high energy phosphates.10"'1 In the present study, mild mechanical stunning was achieved in group 2 and group 3 hearts as indicated by changes in regional shortening and was associated with comparable trends in regional myocardial oxygen consumption. Substrate oxidations using pyruvate and lactate either with or without augmented fatty acids in the coronary perfusate showed the anticipated decline during ischemia and virtually no recovery during reperfusion. These findings, together with those previously reported for glucose oxidation,'1 do not indicate multifold increases in and preference for carbohydrates for energy metabolism during this perfusion interval but rather are in keeping with increased oxidation of long-chain fatty acids10 with consequent product inhibition of pyruvate dehydrogenase21'22 and other regulatory inhibitions of carbohydrate oxidation.
The perfused working swine heart model has been extensively critiqued previously13-16 and will not be reviewed here. The only modifications made in the present report were 1) a different indicator technique for measuring dilution in coronary venous blood from the LAD circulation, using indocyanine green rather than radioactive dextran or ratios of specific activities of palmitate,1415 and 2) an estimate for measuring specific activities of pyruvate and lactate in the coronary perfusate from mixing chamber to myocardium. The amount of dilution/contamination was less than previously reported, probably because of improved methods in sampling LAD effluent more slowly. Specific activities of pyruvate and lactate in blood were based on the assumption that nearly all the exchangeable labeled and unlabeled pyruvate and lactate were contained in plasma and not importantly distributed into metabolites within red blood cells. Pilot studies indicated that only about 12% of pyruvate and 12% of lactate were distributed into erythrocytes, and these we elected to ignore in the calculations of substrate specific activity. The transformation of lactate to pyruvate and pyruvate to lactate by red blood cells does not affect the calculated rates of oxidation estimated for each substrate because of the way specific activity was expressed.
In the past two decades much has been learned about intermediary metabolism and substrate utilization in heart muscle and their changes with diminished oxygen supply.7'22-24 Fatty acid metabolism has no anaerobic reserve during ischemia or hypoxia, and every element in the fatty acid utilization pathway from substrate uptake through entry into and use by the critic acid cycle is depressed. Ratios of NADH/ NAD+ in mitochondria and cytosol increase and act to critically suppress /-oxidation, the chief ratelimiting step during oxygen deprivation. Glucose metabolism, which provides only modest amounts of acetyl coenzyme A for ATP production in settings of mixed substrate availability in aerobic hearts, compensates during all but the most profound states of ischemia by accelerating glycolytic flux. Glucose transport and the activities of hexokinase and phosphofructokinase are sufficient to provide substrate for the reaction governed by glyceraldehyde-3-phosphate dehydrogenase, which becomes the chief rate-limiting step in the glycolytic cascade. Even at increased rates of glycolysis, however, the contribution of glucose to anaerobic ATP production in ischemia is small, although it has been speculated that this cytosolically derived fraction is somehow qualitatively advantageous beyond its stoichiometric amount.
Patterns of substrate utilization in reperfused myocardium are less well defined and until recently were largely confined to surveys employing the short-lived isotopes of PET. Schwaiger et al,4 using ["C]palmitate, reported delayed clearance of fatty acids and altered kinetics for 1 day to 1 week following a 3-hour coronary occlusion in dogs. However, it is not possible with certainty to extrapolate these to fatty acid oxidation.
The time-activity curves of ["C]palmitate in aerobic or ischemic myocardium are not related to individual steps in the fatty acid utilization pathway but rather represent some interrelation among substrate incorporation, activation, lipid storage, mitochondrial transfer, fl-oxidation, and entry into the citric acid cycle. Indeed, using ['4C]palmitate, we showed an increase in fatty acid oxidation during early reflow that would not have been predicted by the clearance curves of ["C]palmitate.10 Weiss et a125 and Schelbert and coworkers,26 using intracoronary and intravenous administrations of ["C]palmitate, described two phases of monoexponential decline of activity presumed to be associated with 83-oxidation and lipid storage. However, during ischemia and hypoxia with constrained and preserved coronary flows, respectively, there should have been sufficient differences in residence times of isotope to render some portions of the time-activity curves morphologically distinct. Such was not the case, and, in fact, the curves were nearly identical. 27 Concern has also been raised about the confounding influence of back-diffusion of nonmetabolized isotope. Such efflux of extracted but nonmetabolized ["C]palmitate, presumably from triglyceride stores, accounts for nearly half of the total available isotope in ischemia and effectively prevents direct assessment of shifts in fatty acid metabolism during reduced oxygen delivery. 28, 29 Moreover, using [14C]palmitate in equilibrium studies,14"16'30-32 we have noticed that about 30 minutes is required for steady-state labeling of all available intracellular carbon pools related to the fatty acid pathway before steady-state production of 14C02 occurs. This is at the outside limit of the half-life for ["C]palmitate and may also bias results.
Glucose metabolism during reperfusion has also been characterized by PET with 18FDG although here, too, concern has been raised about the methodological limitations of the tracer. 18FDG tracks only transmembrane exchange of glucoseand hexokinase-mediated phosphorylation to 18FDG-6-phosphate, where it is unidirectionally trapped.5 '6 Biochemically, this intermediate is a poor marker for glycolysis or glycogen synthesis, but it remains an effective agent in brain tissue, where glycogen synthesis is nonexistent and flux through the hexokinasemediated reaction mirrors that of the entire glycolytic pathway. Such is not the case in heart muscle, where exogenous glucose may enter either glycolysis or the glycogen pool, depending on the level of available or competitive substrates, cardiac work, hormones, insulin, and coronary perfusion.7'22-24 Still, the directional changes of increased glucose utilization with 18FDG during reflow are of interest and have stimulated a plethora of experiments. In two different protocols of myocardial ischemia followed by reperfusion (range, 1-3 hours of coronary occlusion, and one-24 -hour reflow in canine hearts), both Myears et a18 and Schwaiger et al,9 using either [3H]glucose or D-[6-14C]glucose, showed that glucose extraction was increased in reperfused myocardium (270-273% above preischemic control values) but that the lion's share of the glucose taken up participated only in nonoxidative metabolism (57-75% of uptake). Lactate production was fourfold greater in reperfused compared with control hearts. This modest change in glucose oxidation during reflow is in agreement with data recently reported by us in intact swine hearts."
The present study further details the use of other carbohydrate analogues, specifically pyruvate and lactate, in reperfusion studies. Oxidation of both substrates was suppressed as expected during ischemia and remained decreased during reflow. In the case of pyruvate oxidation, this suppression occurred irrespective of whether fatty acid levels in perfusate were physiological or augmented. The magnitude of rates of oxidation for lactate were greater than those observed for glucose" or pyruvate. To estimate the relative contributions of ATP synthesis from these carbohydrate substrates as compared with long-chain fatty acids,10 we arrayed the average CO2 production levels from these substrates and used the following conversions: 129 mol ATP synthesized from 1 mol palmitate; 38 mol ATP synthesized from 1 mol glucose; 15 mol ATP synthesized from 1 mol pyruvate; and 18 mol ATP synthesized from 1 mol lactate. The sum of ATP synthesized from glucose, pyruvate, and lactate amounted to only 19.2% of that generated by fatty acids at conditions of excess fatty acids in perfusate, whereas that contributed by glucose and pyruvate amounted to only 12.9% of that generated by fatty acids at physiological levels of fatty acids in perfusate.
These calculations reflect that in reperfusion, glucose, pyruvate, and lactate offer little to ATP production, which is reliant primarily on oxidation of fatty acids.
